Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25752531 | 0.71 | EGFR (0.31) | — | |
| SCHEMBL4068697 | 0.71 | JAK3 (0.33) | — | |
| SCHEMBL8661034 | 0.70 | TYMS (0.33) | — | |
| SCHEMBL9357079 | 0.67 | MAPT (0.52) | MAPT | |
| SCHEMBL3927195 | 0.65 | ALDH1A1 (0.44) | MAPT | |
| SCHEMBL8371624 | 0.65 | S100A4 (0.48) | — | |
| SCHEMBL261649 | 0.64 | S100A4 (0.52) | — | |
| SCHEMBL10373895 | 0.64 | MEN1 (0.50) | MAPT | |
| SCHEMBL8874228 | 0.64 | TSHR (0.33) | — | |
| SCHEMBL22654547 | 0.63 | ALOX15 (0.37) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2023-07-20 | — | — | US | disclosed |
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2023-07-20 | — | — | US | disclosed |
| WO-2022005308-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | COMVITA LIMITED (NZ) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021002763-A1 | USE OF A COMPOSITION COMPRISING 3,6,7-TRIMETHYLLUMAZINE FOR PREVENTING, AMELIORATING OR TREATING MMP-9 ASSOCIATED CONDITIONS AND INFLAMMATION | COMVITA LIMITED (NZ) | 2021-01-07 | — | — | WO | disclosed |
| WO-2017099612-A1 | MARKER COMPOUNDS OF LEPTOSPERMUM HONEYS AND METHODS OF ISOLATION AND ASSAYING THEREOF | COMVITA LIMITED (NZ) | 2017-06-15 | — | — | WO | disclosed |
| US-5041547-A | Color formers in pressure or heat sensitive recording materials; discoloration inhibition; color fastness | APPLETON PAPERS INC. (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0192328-B1 | CHROMOGENIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-09 | — | — | EP | disclosed |
| EP-0192328-A1 | Chromogenic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226065-A1 | ANTI-INFLAMMATORY COMPOSITIONS, METHODS AND USES THEREOF | PTGES2, TPMT, PARK7 | MAPT 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.